Drug Development Questions And The FDA - The End Of The Black Hole

March 31, 2015

Commonly during drug development, significant issues arise for which FDA input is desired but that do not merit a full face-to-face multidisciplinary milestone meeting. In many cases, sponsors are reluctant to reach out to the FDA because of a concern that their questions will disappear into a black hole while the FDA focuses on PDUFA time-line mandated activities. The new FDA guidance, Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products, appears to provide some degree of certainty around the process for requesting this type of input and time frames for responses from the FDA. As described in the section of the guidance on Type C meetings, sponsors may request a written response to these types of questions and if the FDA agrees to answer the questions, the meeting granted letter will specify the date that the written responses are to be transmitted to the sponsor (provided that adequate briefing information is sent to the FDA in a timely manner). While the 75-day time frame for a response is probably not as quick as most sponsors would like, it does provide definition to a process that a company can plan around. As with all FDA interactions, we recommend taking the time to formulate the strategy which best aids in successful drug development, incorporating questions such as:

  • Whether requesting a written response or a full meeting with the FDA provides the best strategic option for the sponsor; and
  • How best to position questions and background materials so that written responses and/or meeting minutes from the Agency fully address and answer the sponsor’s questions.

Learn more about ProPharma Group's regulatory strategy and submission services. If you have any questions or thoughts on this blog post or others, please contact us

TAGS:

Person typing on laptop with transparent icons floating around.

August 2, 2022

Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry

Guidance Document August 2022 This guidance provides instructions for the electronic submission of expedited individual case safety reports (ICSRs) from investigational new drug (IND)-exempt...

April 13, 2016

FDA Works to Reduce Medical Errors, Part One: Background & Overview of FDA’s Proprietary Naming Guidance

In September 2007, the Prescription Drug User Fee Act (PDUFA IV) was reauthorized and expanded, broadening and strengthening FDA’s drug safety program. As part of PDUFA’s reauthorization, the Agency...

May 14, 2015

FDA Sets A Deadline For Electronic Submission Of Drug Applications

In a final guidance published in the Federal Register on May 5, FDA laid out the rules and specifications for providing regulatory submissions in electronic format. Perhaps more important than the...